🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

10th TD on the year. 50th as a Raven. Mark Andrews. #RavensFlock

Mark Andrews joins Rob Gronkowski (2011) as the only Tight Ends since the merger to have a TD reception in 6 straight games in a single season

Ravens 2024/25 Playoff Hype 🐦‍⬛ - 📸 @ravens 💻 RD @simplyas10

FYI to all my Amer. Urol. Assn. Urology and Mayo Clinic surgical colleagues. It is now recommended that patients in GLP-1 meds can continue them through the preoperative period. Similar recs for SGLT2 inhibitors (stop the day prior to surgery and resume once eating)

Going on the fridge

Excited to share our recent multi-center study showing PSMA+EVs are prognostic and predictive in oligometastatic prostate cancer treated with SBRT. Validation studies are ongoing. A future for EV-guided therapy! Mayo Clinic Urology Mayo Clinic Radiation Oncology aacrjournals.org/clincancerres/…

Check out our study now published in Clinical Cancer Research The first liquid predictive biomarker for metastasis directed therapy in oligometastatic prostate cancer asses with samples from the STOMP and ORIOLE trials Awesome collaborators in this international study made this happen

BREAKING: 🇺🇸 President Trump signs crypto executive order to create a national digital asset stockpile, Fox reports.

And imagine how much better OS and PFS will be for SBRT when trials of the future utilize biomarkers that stratify and enroll the patients who are likely to respond rather than enrolling all comers! Fabrice Lucien, PhD Piet Ost Oliver Sartor pubmed.ncbi.nlm.nih.gov/39820657/

TiP: Intra-pt comparison of urinary radioact after 18F-piflufolastat & 18F‑flotufolastat PET in low PSA BCR after RP Jack Andrews UroToday.com #GU25 ☑️n=60 screen; n=52 scanned ☑️Key elig criteria: low PSA (≤ 0.5 ng/mL) BCR who had RP ≥ 6 months before enrollment, w/ undetec

Had an amazing time presenting my abstract at #ASCOGU25 ! Learned so much about the latest in #ProstateCancer research. Excited for the future of oncology. Grateful to my PIs for the invaluable guidance and constant support throughout this journey! Jack Andrews #PSMA #Pluvicto

Intra-patient comparison of urinary radioactivity after 18F-piflufolastat and 18F‑flotufolastat PET in men with low PSA biochemical recurrence of #ProstateCancer who have had radical prostatectomy. Presented by Jack Andrews Mayo Clinic. #GU25 written coverage by Zach Klaassen >

Thanks UroToday.com for promoting our recent work on PSMA+ EV for risk stratification and treatment selection in oligometastatic prostate cancer. Mayo Clinic Urology Mayo Clinic Radiation Oncology Aadel Chaudhuri, MD PhD urotoday.com/recent-abstrac…

Proud of Yohan Kim, PhD demonstrating the power of targeted EV isolation for detection of cancer-specific markers and enhance non-invasive prostate cancer diagnosis #ISEV2025 Mayo Clinic Urology

Amer. Urol. Assn. 2025 Annual Meeting - BOND-003 Cohort C: listen to our podcast with Mark Tyson on this conditionally replicating adenovirus in BCG-unresponsive NMIBC. spotifycreators-web.app.link/e/JkEwxljnUSb jim catto Prof. Prokar Dasgupta OBE Professor Henry Woo Phillip Pierorazio Scott Eggener Mohamad Allaf Samir Taneja

PSMA-positive extracellular vesicles as biomarkers in oligometastatic #ProstateCancer. Jack Andrews Mayo Clinic joins Zach Klaassen Georgia Cancer Center to discuss his team's Clinical Cancer Research publication examining plasma samples from the #ORIOLE trial and #STOMP-protocol patients to

Join us in Melbourne for #USANZ26! Convenor Renu Eapen and the organising committee invite you to the 2026 ASM at the Melbourne Convention & Exhibition Centre, 28 Feb – 3 Mar 2026. Discover what’s in store at asm.usanz.org.au

PSMA-positive extracellular vesicles as biomarkers in oligometastatic #ProstateCancer. Jack Andrews Mayo Clinic joins Zach Klaassen Georgia Cancer Center to discuss his team's Clinical Cancer Research publication examining plasma samples from the #ORIOLE trial and #STOMP-protocol patients to

#BOND003 Cohort C trial results for cretostimogene grenadenorepvec in BCG-unresponsive #BladderCancer. Mark Tyson Mayo Clinic and Sam S. Chang MD, MBA Vanderbilt Urology discuss promising results for #BladderCancer patients with BCG-unresponsive CIS, with a 75.5% complete response rate and

Great work. Echos the Pound study from 25 years ago Natural history of post RP BCR was a median CSS of 13 yrs with 8 yrs from BCR to Mets on conventional imaging (with no treatment!) and 5 yrs from Mets to death from PCa (with essentially toxic placebos) pubmed.ncbi.nlm.nih.gov/10235151/